News Galapagos unveils plan to split, hiving off its drugs unit Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its drug development and cell therapy operations.
News J&J says Rybrevant combo has survival edge over Tagrisso Rybrevant plus Lazcluze extended median OS by more than a year compared to Tagrisso in the MARIPOSA trial in treatment-naive, EGFR-mutated NSCLC.
News GSK bags breakthrough status for bone cancer drug GSK has claimed its second breakthrough designation from the FDA for B7-H3-targeted ADC, this time in osteosarcoma.
R&D Sponsored 12 Questions with Peter Wickersham Peter Wickersham is the Vice President and General Manager of Gilead Sciences UK & Ireland, and a leader in HIV treatment, liver disease, and oncology.
News CARsgen gets a win for CAR-T in solid tumours CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satri-cel has shown efficacy in gastric cancer, setting up a filing in China.
News Hutchmed cashes in a Chinese JV to help fund its pipeline Hutchmed has agreed to divest its share of a non-core Chinese JV through a pair of deals that will give it a cash injection to plough into R&D.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.